Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novartis has signed a definitive agreement to acquire personalized diagnostics lab services firm Genoptix for approximately $470 million.

Novartis will pay $25 per share in cash for all of the outstanding shares of the Carlsbad, Calif.-based company. The purchase price represents an approximately 27 percent premium to Genoptix's Friday closing price on the Nasdaq of $19.76.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.